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Abstract
Patients with Langerhans cell histiocytosis (LCH) harbor BRAF V600E and activating mutations
ofMAP2K1/MEK1 in 50% and 25% of cases, respectively. We evaluated a patient with treatment-
refractory LCH for mutations in the RAS-RAF-MEK-ERK pathway and identified a novel mutation
in theMAP2K1 gene resulting in a p.L98_K104 >Q deletion and predicted to be auto-activating.
During treatmentwith theMEK inhibitor trametinib, the patient's disease showed significant pro-
gression. In vitro characterization of the MAP2K1 p.L98_K104 > Q deletion confirmed its effect
on cellular activation of the ERK pathway and drug resistance.
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1 INTRODUCTION
Langerhans cell histiocytosis (LCH) is a rare disorder characterized
by the clonal expansion of Langerhans cells and is associated with a
wide range of clinical symptoms.1 Genomic analysis of patients with
LCH have identified several functionally relevant mutations,2 includ-
ing BRAF V600E, which are present in over 50% of LCH patients,3,4
MAP2K1 (MEK1) mutations, which occur in about 25% of patients,5–7
as well as mutations in ARAF,8 and MAP3K1.7 The identification of
the BRAF V600E mutation in LCH has led to the application of tar-
geted therapy,9 in particular the use of vemurafenib.10 MAP2K1muta-
tions of LCH patients are activating mutations and mutually exclusive
of the BRAF V600E mutation.6 Mutations of genes in the RAS-RAF-
MEK-ERK pathway in LCH suggest that targeted therapy with MEK
inhibitors may benefit LCH patients. Studies of targeted therapy for
MAP2K1 using trametinib have been done for several cancer types11,12
including histiocytosis.13,14 Here, we describe a patient with LCH har-
boring a novel mutation in MAP2K1, who underwent treatment with
Abbreviations: ARAF, proto-oncogene belonging to RAF family; BRAF, proto-oncogene
belonging to RAF family; BRAFV600E, BRAF harboring an activatingmutation at amino acid
600; ERK, signaling kinases ERK1 (MAPK3) and ERK2 (MAPK1); LCH, Langerhans cell
histiocytosis; MAP2K1, gene encodingMEK1;MAP3K1, gene encodingMEK kinase (MEKK);
MEK1, mitogen-activated protein kinase kinase; encoded by theMAP2K1 gene;MEK-MUT,
mutatedMEK1 harboring theMAP2K1 p.L98_K104>Qmutation;MEK-WT, wild-type
MEK1; PET-CT, positron emission tomography/computed tomography; RAF, kinases involved
in signaling including ARAF, BRAF, and c-RAF; RAS, small GTPases involved in signaling
including HRAS, KRAS, and NRAS
trametinib resulting in disease progression, and subsequent functional
analysis of the novelMAP2K1mutation.
2 MATERIALS AND METHODS
2.1 Mutation analysis
A sample of lymphnode fromapatient diagnosedwith LCHwas sent to
FoundationMedicine (Cambridge,MA) for FoundationOne R© sequenc-
ing analysis of a 315-gene panel.
2.2 Cloning
Thewild-type (MEK-WT)MEK1-GFPplasmid,15 a gift fromRonySeger
(Addgene plasmid #14746, Cambridge, MA), was used to create the
MEK1 mutant (MEK-MUT). Briefly, a double-stranded 44 bp oligonu-
cleotide (Thermo Fisher; Waltham, MA) replicating the genomic dele-
tion of the patient was substituted into the MEK-WT plasmid to gen-
erate the MEK-MUT version. Isolated clones of the MEK-MUT were
sequence verified at the University of Arizona Genetics Core (Tucson,
AZ).
2.3 Cell assays
HEK293A cells (Thermo Fisher) were grown in DMEM (Corning, Man-
assas, VA) supplemented with 10% FBS (Atlas Biologicals, Ft. Collins,
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F IGURE 1 Identification of a novel mutation inMAP2K1 (MEK1) in a patient with Langerhans cell histiocytosis (LCH). A, PET scan of LCH patient
prior to treatmentwith afuresertib and subsequent scans, at both 6 and 9months post AKT inhibitor treatment, showing partial response.Written
informed consent was provided for publication of the images. B, Sequencing analysis of a sample from the LCH patient indicates an amino acid
deletion/change (L98_K104 >Q) due to a 18 bp deletion in exon 3 ofMAP2K1 (MEK1). This region of the MEK protein corresponds to the p-loop
binding site for phosphorylation of serines 217/222 (p-MEK). C, PET scan of the LCH patient prior to treatment with trametinib and 8 weeks post
trametinib treatment. D,Mutations inMAP2K1 protein that have been identified in LCH patient samples
CO) and 2 mM L-Glutamine (Thermo Fisher) at 5% CO2 and 37˚C.
HEK293A cells were transiently transfected with purifiedMEK-WT or
MEK-MUT plasmids using Xtremegene-HP (Roche Life Sciences, Indi-
anapolis, IN). At 48 hr, cells were treated with the inhibitors: trame-
tinib; U0126; MK-2206; or SCH772984 (all drugs from Selleckchem,
Houston, TX) for 1 hr. Cells were collected for protein analysis. Sta-
ble expressing cells were generated through Neomycin selection using
0.4mg/ml G418 (Thermo Fisher).
2.4 Western blot/AlphaLISA
Cellular lysates from transfected cells were normalized for equal
loading on gels and AlphaLISA (PerkinElmer; Waltham, MA) kit. Gels
were transferred to PVDF membrane (Bio-Rad, Hercules, CA) and
probed with antibodies against MEK/p-MEK; ERK/p-ERK; AKT/p-
AKT; or COX IV (Cell Signaling Technology, Danvers, MA). Blots
were developed using ECL (Thermo Fisher) and imaged. AlphaLISA
assay for p-ERK (PerkinElmer) was analyzed as per manufacturer's
instruction.
3 CASE DESCRIPTION
A 16-year-old male was diagnosed with multifocal LCH primarily
involving lymph nodes. The patient was treatedwith LCH-III therapy16
and initially responded to treatment. One year later, the patient pre-
sentedwith painful right-sided neck swelling and a biopsy of the lesion
confirmed recurrence of LCH. The patient was then treated with the
oral pan-AKT inhibitor afuresertib as part of a clinical trial.17 The
patient responded to afuresertib therapy and completed a total of
30 weeks of treatment (Figure 1A). Several months later, the patient
relapsed and was treated with cytarabine 150 mg/m2/day for a 5-day
course. After two courses, the patient did not show a good response,
and vincristine and steroids were added to the therapy. Afterward,
the patient received two cycles of clofarabine, after which he was
lost to follow-up. Three years after his initial diagnosis, the patient
presented again with LCH symptoms and had cancer-related gene
mutation analysis performed at Foundation Medicine. The genomic
analysis identified a novel mutation in MAP2K1 (MEK1): an 18 bp
deletion c293_310del in exon 3 resulting in a p.L98_K104 > Q in-
frame deletion (Figure 1B). Based upon the gene target, the patient
received the MEK inhibitor, trametinib, 2 mg once daily. PET-CT
whole body evaluation after 8 weeks of treatment showed progres-
sive disease (Figure 1C). Treatment with trametinib was discontinued,
and the patient was further treated with a combination of clofara-
bine and cytarabine for three cycles for disease control. Thereafter,
the patient's disease was in control to obtain a haploidentical trans-
plant, and more than a year after transplant the patient was doing
well.
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F IGURE 2 Functional analysis of the L98_K104 > Q mutation of MAP2K1 (MEK1). A, Western blot analysis of untransfected HEK293A cells
(293A), HEK293A transiently transfected with wild-typeMAP2K1 (MEK-WT) and HEK293A transiently transfected withMAP2K1 containing the
L98_K104>Qmutation (MEK-MUT) treatedwith 100 nM trametinib (T), or 30 𝜇MU0126 (U) for 1 hr. Lysates from each treatmentwere analyzed
for protein expression using antibodies to p-ERK, total ERK, pMEK, and total MEK. Antibody to COX IV was used as a loading control. Western
blot panel shows increased expression of the MEK-WT and MEK-MUT transfectants. The p-MEK-MUT has a two- to threefold increase versus
p-MEK-WT resulting in a significant activation of p-ERK in the MUT samples. For 293A and MEK-WT, both U0126 and trametinib show loss of
activation of p-ERK by inhibiting p-MEK expression. TheMEK-MUT form shows no sensitivity to either MEK inhibitor. B, AlphaLISA analysis of p-
ERKactivation levels. Cell lysates (5𝜇gprotein/sample) used in thewesternblotswereanalyzed for p-ERK levels using adouble antibodyAlphaLISA
assay (PerkinElmer) and results normalized tountreated293Acell lysate. Similar to thewesternblot results, theAlphaLISA showsp-ERKactivation
in the 293A and MEK-WT samples are completely inhibited by both U0126 and trametinib. The transient MEK-MUT showed no sensitivity to
trametinib compared to no drug treatment, while showing partial inhibition by U0126. C, Analysis of MEK-MUT activity in stably expressing cells.
Cells transfectedwith eitherMEK-WTorMEK-MUTwere grown inmedia containingG418 for generating stable expressing cells. Stably expressing
MEK-WT or MEK-MUT were treated with no drugs (ND), 30 𝜇MU0126 (U), 100 nM trametinib (T), the ERK inhibitor SCH772984 (E) at 200 nM,
and the AKT inhibitor MK-2206 2HCl (A) at 100 nM. Western blot analysis of p-ERK expression showed a similar pattern to that of the transient
samples except for decreased expression levels of transfected MEK and transfected p-MEK. The MEK inhibitors U0126 and trametinib inhibited
p-ERK activation inMEK-WT cells but not inMEK-MUT cells as with the transient transfected cells
4 RESULTS AND DISCUSSION
In order to evaluate the function of the novel MAP2K1 mutation,
we duplicated the p.L98_K104 > Q mutation using an expression
construct for GFP-MEK.15 HEK293A cells were transiently trans-
fected with either the wild-type GFP-MEK construct (MEK-WT), the
p.L98_K104 > Q mutant (MEK-MUT), or left untransfected and were
treatedwithMEK inhibitorsU0126or trametinib. BothMEK inhibitors
were able to decrease p-ERK expression in untransfected cells and
MEK-WT-expressing cells, but not in the MEK-MUT cells (Figure 2A).
MEK-MUTcells alsoexpressedmuchhigher levels of p-ERKthaneither
MEK-WT or untransfected HEK293A cells using an AlphaLISA p-ERK
assay (Figure2B). Furthermore, bothMEK inhibitors greatly decreased
p-ERK levels in untransfected and MEK-WT-expressing HEK293A
cells, while having a mild effect on MEK-MUT cells. Transiently trans-
fected cells were further grown in selection media to establish cells
stably overexpressing either MEK-WT orMEK-MUT. These cells were
similarly treated with MEK inhibitors U0126 and trametinib as well as
the ERK inhibitor SCH772984 and the AKT inhibitor MK-2206. The
MEK inhibitors decreased expression of p-ERK in the stably express-
ing MEK-WT cells but not in the stably expressing MEK-MUT cells
(Figure 2C). Taken together, these functional studies indicate that the
MAP2K1 p.L98_K104 > Q mutation leads to increased p-ERK activa-
tion that is unaffected byMEK inhibitors.
The p.L98_K104 >Qmutation inMAP2K1 has not been previously
described but it is found in a region of theMAP2K1 genewhere several
other activatingmutations have been found5,6,18,19 (Figure 1D). In vitro
functional studies show that theMEK inhibitor U0126 can inhibit ERK
activation resulting from these mutations in this region of MAP2K1.6
Another study showed that the p.F53_Q58 > L, p.Q58_E62del, and
p.C121S/G128V mutations in MAP2K1 constituently activated ERK
and were susceptible in vitro to MEK inhibitors including trametinib.20
Interestingly, a recent report describes the complete remission of
an LCH patient with an MAP2K1 p.E102-I103del mutation treated
with trametinib.14 The described MAP2K1 p.E102-I103del deletion
involves six bases that fall inside the p.L98_K104 > Q deletion and
has been shown to be an activating mutation.5,6 The difference in
the response of these two patients, having similar but not identi-
cal MAP2K1 mutations, to trametinib could be due to several factors
including the structural change in MAP2K1 protein that the larger
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p.L98_K104 > Q deletion would have on MAP2K1 activity or trame-
tinib binding. The expression of the MAP2K1 p.L98_K104 > Q muta-
tion identified in this LCH patient leads to hyper-activated p-MAP2K1
and increases activation of p-ERK. As seen in these studies, and con-
sistent with the clinical results, this activatingMAP2K1mutation is not
responsive to inhibitionwithMEK inhibitors, including trametinib. Fur-
ther functional investigation of these MAP2K1 mutations is needed.
Furthermore, it would be of interest to understand the role that the
previous therapeutic treatment with afuresertib may have played in
the development of this particular resistance-associated mutation.
These results emphasize the importance of the functional assessment
of genomic data in assigning treatment for patients with LCH or other
cancers, as well as provide evidence for choice of inhibitor in patients
with this or similar mutations.
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